US 9611260
Compositions and methods for inhibition of the JAK pathway
granted A61PA61P27/00A61P27/02
Quick answer
US patent 9611260 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61P, A61P27/00, A61P27/02, A61P27/04, A61P27/06